Research programme: anti-HIV compounds - ViiV Healthcare

Drug Profile

Research programme: anti-HIV compounds - ViiV Healthcare

Alternative Names: BMS 986197

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ViiV Healthcare
  • Class Small molecules
  • Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 22 Feb 2016 Preclinical trials in HIV infections in USA (unspecified route)
  • 22 Feb 2016 Preclinical pharmacokinetics data from presented at the Conference on Retroviruses and Opportunistic Infections
  • 22 Feb 2016 ViiV Healthcare acquired the HIV R&D portfolio of Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top